$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
乳腺癌患者使用瑞博西利需要阅读的药品说明书
2025-10-19 11:44:20
Check Details
乳腺癌患者服用瑞博西林的禁忌和注意事项
2025-10-19 11:44:20
Check Details
瑞博西利是帕博西尼耐药后的治疗选择吗?
2025-10-19 11:44:20
Check Details
瑞博西林可以作为晚期乳腺癌的一线治疗用药吗?
2025-10-19 11:44:20
Check Details
CDK4/6抑制剂瑞博西利经FDA批准的适应症有哪些?
2025-10-19 11:44:20
Check Details
什么情况下可以采用CDK4/6抑制剂瑞博西林进行治疗?
2025-10-19 11:44:20
Check Details
瑞博西林在治疗HR+/HER2晚期或转移性乳腺癌这方面有着显著的疗效
2025-10-19 11:44:20
Check Details
瑞博西林对于晚期HER2阳性乳腺癌可显著延长患者总生存期
2025-10-19 11:44:20
Check Details
晚期乳腺癌一线治疗用药:CDK4/6抑制剂瑞博西利
2025-10-19 11:44:20
Check Details
乳腺癌患者如何正确使用瑞博西林进行治疗?
2025-10-19 11:44:20
Check Details
患者服用瑞博西林一个周期的费用
2025-10-19 11:44:20
Check Details
瑞博西利在绝经前HR阳性晚期乳腺癌一线治疗中有着巨大潜力
2025-10-19 11:44:20
Check Details
1
2
...
1994
1995
1996
1997
1998
1999
2000
...
4154
4155
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
LONSURF® (Trifluridine/Tipiracil): Unveiling the Global R&D and Supply Chain Behind the Oral Chemotherapy
2
FDA Approves Lilly's Inluriyo (Imlunestrant) for ESR1-Mutant Advanced Breast Cancer
3
Tivozanib: The Evolution of Highly Selective VEGFR Inhibition in Renal Cell Carcinoma
4
Trifluridine/Tipiracil: Managing Side Effects in Metastatic Colorectal and Gastric Cancer
5
Adagrasib Medication Management Guide for Special Populations
6
Olutasidenib (Rezlidhia): A Targeted Drug for IDH1-Mutated Relapsed/Refractory AML
7
Capmatinib Redefines Precision Therapy for MET-Mutated Lung Cancer
8
Cabozantinib: Pivotal Advancements and Global Implications in Multi-Cancer Treatment with Multi-Kinase Inhibition
9
Tucatinib (Tukysa): A Precision Medicine for HER2-Positive Breast & Colorectal Cancer
10
Global Breakthrough: Pralsetinib - Precision Medicine for RET Mutation-Driven Cancers
11
Elacestrant: Precision Therapy for ESR1-Mutant Resistant HR+/HER2- Advanced Breast Cancer
12
Selpercatinib Complete Medication Guide: Indications, Dosage and Safety Information for RET Inhibitor